3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
12
Neoplasm Metastasis
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
HER2-positive Gastric Cancer
1
HER2-positive Breast Cancer
1
HER2-positive Advanced Gastric Cancer
1
HER2 Overexpression
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Interventions
Thyroidectomy
5
Iodine-131
5
Surgical Procedures, Operative
3
selpercatinib
2
lenvatinib
2
anlotinib
2
Ultrasonography
2
Transurethral Resection of Prostate
2
Sorafenib
2
Molecular Diagnostic Techniques
2
Interviews as Topic
2
Focus Groups
2
Biopsy, Fine-Needle
2
trastuzumab deruxtecan
1
trametinib
1
pralsetinib
1
pembrolizumab
1
gallium Ga 68 dotatate
1
dabrafenib
1
Triiodothyronine
1
Thyroxine
1
Thyrotropin Alfa
1
Surveys and Questionnaires
1
Routinely Collected Health Data
1
Radiotherapy, Adjuvant
1
Quality of Life
1
Patient Reported Outcome Measures
1
Observation
1
Nivolumab
1
Minimally Invasive Surgical Procedures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Thyroid Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled